(Public, LON:IXI)   Watch this stock  
Find more results for Charles Lowther�
+0.50 (1.54%)
Apr 24 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 33.00 - 33.00
52 week 30.00 - 68.00
Open 33.50
Vol / Avg. 1,287.00/10,608.00
Mkt cap 5.30M*
P/E     -
Div/yield     -
EPS     -
Shares 15.06M
Beta     -
Inst. own     -
Jun 4, 2015
Half Year 2015 IXICO PLC Earnings Release (Estimated) - 8:00AM GMT+1 - Add to calendar
Mar 6, 2015
IXICO PLC Annual Shareholders Meeting
Feb 10, 2015
Full Year 2014 IXICO PLC Earnings Release

Key stats and ratios

Q3 (Sep '14) 2014
Net profit margin -67.16% -
Operating margin -73.72% -
EBITD margin - -
Return on average assets -30.51% -
Return on average equity -41.79% -
Employees 52 -
CDP Score - -


4th Floor, 15 Long Lane, Griffin Court
United Kingdom - Map
+44-20-37637499 (Phone)
+44-20-72092473 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


IXICO plc is engaged in providing clinical trial services and technology to evaluate imaging endpoints as part of their drug development pipelines. While the clinical focus is dementia, the Company also supports clinical studies for other disease areas in the field of neuro-degeneration. The Company�s medical image management and analysis products are used by the global pharmaceutical industry to select patients for clinical trials and to assess the safety and efficacy of drugs in development. The Company�s technologies include TrialWire and TrialTracker. This technology has been used in the collection of patient data from more than 400 hospital sites around the world in several of the clinical trials of Alzheimer�s disease treatments. The Company is also translating its technology into decision-support tools for the diagnosis of dementia. These products, including the new medical device, Assessa, will assist healthcare professionals to provide diagnosis.

Officers and directors

Andy Richards Chairman of the Board
Derek Hill Ph.D. Chief Executive Officer, Director
Susan Day Lowther Chief Financial Officer
Age: 54
Roger Humm Vice President - Finance
Jane Whitrow Vice President - Business Operations, Company Secretary, Director
Michelle Lax Vice President - Clinical Operations
Charles Spicer Vice President - Corporate Development, Director
Age: 48
Kate McLeish PhD. Vice President - Technology
John Hall Vice President - Business Development
Maina Bhaman MBA Non-Executive Director